IMV announced ordinary income (loss) of ¥2,911 million for the fiscal year ending September 2026. Although this represented a 13.3% increase year on year, it was below the IFIS consensus of ¥3,000 million. The company also indicated an ordinary income (loss) forecast of ¥3,120 million for the fiscal year ending September 2027, 4% above the IFIS consensus.
IMV reported ordinary income (loss) of ¥2,911 million for the fiscal year ending September 2026, an increase of 13.3% from the previous fiscal year. The market's IFIS consensus was ¥3,000 million, and the actual result was below that level. As a result, part of the company's full-year outlook diverged from market expectations.
In its earnings forecast for the fiscal year ending September 2027, announced on the same day, the company expects ordinary income (loss) of ¥3,120 million, an increase of 7.2% from the previous fiscal year. This is expected to be 4% above the IFIS consensus, indicating that the outlook for the next fiscal year is above market expectations.
Related stocks include Daiken Medical, CellSeed, Nippon Seimitsu and Rhythm. Investors are watching how the gap between the company's subsequent earnings performance and the IFIS forecast develops.